Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome?-Reference-Cited by-同舟云学术

Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome?

Published:2012-07 Issue:1 Volume:104 Page:62-66
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Clarke Katy,Taremi Mojgan,Dahele Max,Freeman Marc,Fung Sharon,Franks Kevin,Bezjak Andrea,Brade Anthony,Cho John,Hope Andrew,Sun Alexander

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference30 articles.

1. .

2. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute. , based on November 2009 SEER data submission, posted to the SEER web site; 2010.

3. A controlled study of post-operative radiotherapy for patients with completely resected non-small cell lung carcinoma;Dautzenberg;Cancer,1999

4. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group Cancer 1984;54:1802–13.

5. Stage I non-small cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence;Harpole;Cancer,1995

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study;Radiation Oncology Journal;2024-03-31

2. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation;Radiotherapy and Oncology;2024-01

3. Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy;Advances in Radiation Oncology;2024-01

4. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial;Nature Communications;2023-09-02

5. Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy;Cancer and Metastasis Reviews;2023-06-01